Recent Quotes
My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

15.19 +0.07 (+0.46%)
Streaming Delayed Price Updated: 11:50 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗
Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S. 
Via Stocktwits
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Examining the Future: KalVista Pharma's Earnings Outlook ↗
 
Via Benzinga
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year ↗
Via Stocktwits
News headline image
KalVista Pharma's Earnings: A Preview ↗
 
Via Benzinga
News headline image
Recap: KalVista Pharma Q3 Earnings ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by... 
Via MarketMinute
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
KalVista Posts 154% Expense Jump in Q1 ↗
Via The Motley Fool
News headline image
KalVista Pharmaceuticals Inc (NASDAQ:KALV) Stock Rises 7.4% on Strong EKTERLY Launch Despite Q1 Earnings Miss ↗
KalVista stock rises 7.4% on strong EKTERLY launch, despite Q1 revenue miss and wider EPS loss. Early HAE treatment adoption exceeds expectations. 
Via Chartmill
News headline image
Earnings Scheduled For September 11, 2025 ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
 
Via Benzinga
News headline image
Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗
FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients. 
Via Benzinga
News headline image
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated ↗
Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous... 
Via Stocktwits
News headline image
KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment ↗
The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare disease. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease ↗
KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US. 
Via Benzinga
News headline image
How KalVista Pharma Is Taking On A Rare But Deadly Disease ↗
The company is working on the first new on-demand treatment for hereditary angioedema in 11 years. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Super Micro Computer And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 ↗
KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the fourth quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>